Summary & Overview
HCPCS Level II C9062: Daratumumab 10 mg with Hyaluronidase Injection
HCPCS Level II code C9062 denotes the subcutaneous injection formulation of daratumumab with hyaluronidase-fihj (daratumumab 10 mg plus hyaluronidase-fihj). This code captures a combination oncology biologic designed for subcutaneous administration, which can reduce administration time and facility resources compared with intravenous infusions and is increasingly relevant for oncology treatment workflows nationwide. The code matters for billing, site-of-service classification, and payer coverage policies affecting access to modern multiple myeloma therapies.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what the code represents, payer coverage considerations, and typical service settings. The publication also highlights benchmarking and policy context where available, clinical context for subcutaneous daratumumab use, and common billing modifiers associated with injection administration. Where input data is missing, the report notes that those elements are not available in the source.
This national summary is intended to inform billing staff, revenue cycle managers, and policy analysts about the clinical nature of C9062, the typical delivery environment, and the payer landscape relevant to claims and coverage decisions for subcutaneous daratumumab with hyaluronidase-fihj.
Billing Code Overview
HCPCS Level II code C9062 represents the injection formulation of daratumumab combined with hyaluronidase-fihj, packaged as daratumumab 10 mg with hyaluronidase-fihj. This entry describes a subcutaneous immunotherapy preparation combining an anti-CD38 monoclonal antibody (daratumumab) with hyaluronidase to facilitate subcutaneous administration.
-
Service type: Therapeutic injection (subcutaneous/SC delivery of oncology biologic)
-
Typical site of service: Ambulatory infusion centers, hospital outpatient departments, and physician offices capable of administering subcutaneous oncology injections
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with relapsed or refractory multiple myeloma presenting to an oncology ambulatory infusion center for scheduled subcutaneous administration of daratumumab with recombinant human hyaluronidase (C9062). The patient has prior intravenous daratumumab exposure or is receiving daratumumab as part of combination therapy (for example, with lenalidomide or bortezomib). Pre-visit nursing phone screening confirms recent labs (CBC, CMP), review of prior infusion reactions, and current medications. On arrival, nurse triage verifies vital signs, reviews allergy history, obtains weight, and confirms consent and medication reconciliation. An oncology pharmacist compounds the fixed-volume subcutaneous daratumumab with hyaluronidase per institutional protocol. The infusion nurse prepares the subcutaneous injection and administers it in the clinic’s infusion chair or procedure room; observation for 30–60 minutes follows to monitor for injection-site reactions or systemic hypersensitivity. Documentation includes indication, dose administered (converted to billing units: 10 mg units per C9062), lot numbers, route (subcutaneous), start and stop times, and any adverse events. Typical sites of service include outpatient hospital infusion centers, physician office infusion suites, and freestanding oncology clinics. Common payer interactions may involve prior authorization, medical benefit billing under HCPCS C9062, and use of applicable modifiers to denote circumstances (for example, billing for reduced services, discontinuation, or professional/technical components when applicable).
Coding Specifications
| Modifier |
|---|